American BioMed Inc. Signs New United Kingdom Distributor.

THE WOODLANDS, Texas--(BW HealthWire)--June 16, 1998--American BioMed Inc. (OTC Bulletin Board: ABMI), Tuesday announced that CLS Medical Ltd. of Newcastle, England has joined American BioMed's global distribution network.

Founded in 1982, CLS Medical Ltd., specializes in marketing leading edge, vascular surgical products. With sales representatives throughout the United Kingdom, CLS will offer complete promotional coverage for American BioMed's 100% silicone balloon catheter product line.

Chris Bond, managing director of CLS stated, "We are excited about the opportunity to promote a product line that we believe is safer to use and clinically superior to other products currently on the market." CLS has placed initial stocking orders and product training is scheduled to be completed in June.

Commenting on the addition of CLS, Marshall Kerr, vice president of Sales and Marketing for American BioMed said, "We will continue to add quality distributors like CLS to further increase our market share. Current evaluations in Germany and France are expected to be finalized by the end of the third quarter, which will complete our European distribution network." According to Kerr, the United Kingdom represents one of the largest markets in Europe for the company's products, with France and Germany representing a close second.

Currently, American BioMed has 10 distributors covering the North American market. With the addition of CLS, the company's 15 international distributors provide distribution in Spain, Italy, Turkey, Australia, New Zealand, Belgium, Denmark, Greece, Japan, Luxembourg, The Netherlands, Norway, Sweden, Korea, Taiwan, India, the Caribbean, and now the United Kingdom.

American BioMed utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The company's products include 100%-silicone catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal, the OmniCath(R), an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The company has over 25 patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the company's accounting policies, and other risks detailed in the company's Securities and Exchange Commission filings.

    CONTACT:  American BioMed Inc.
               Steven B. Rash, 281/367-3895
                   or
               Coffin Communications
               Matt Lepo, 818/789-0100
                   or
               Coffin/Mottola Communications
               Christi Mottola, 714/851-1109